Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT04835129Phase 2Active, not recruiting
- Sponsor
- Medical College of Wisconsin
- Start
- Jan 2022
- Primary completion
- Apr 2027
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of isatuximab, elotuzumab in multiple myeloma (MM), sponsored by Medical College of Wisconsin. Started Jan 2022; status: active, not recruiting.
02
Drugs
isatuximabelotuzumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04835129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04835129.